Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI of Sevikar and Crestor in Healthy Volunteers
NCT02089399Phase 1Completed
- Sponsor
- Daewoong Pharmaceutical
- Start
- May 2014
- Primary completion
- Jun 2014
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of olmesartan medoxomil + amlodipine and rosuvastatin in hypertension (HTN) and hypercholesterolemia (2 arms), sponsored by Daewoong Pharmaceutical. Primary endpoints: Area Under the Curve over the dosing interval at 24 hours and Maximum steady-state plasma concentration at 24 hours. Started May 2014; status: completed.
02
Drugs
olmesartan medoxomil + amlodipinerosuvastatin
03
Conditions
hypertension (HTN)hypercholesterolemia
Beyond the preview
Go deeper on NCT02089399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02089399.